<div id="readability-page-1"><div><p>Natera, Inc. announced the publication of findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study in JAMA Oncology. This publication builds on the initial presentation of results at the 2025 American Society of Clinical Oncology's Gastrointestinal Cancers Symposium (ASCO GI) earlier this year. CALGB (Alliance)/SWOG 80702 assessed the predictive value of postoperative personalized circulating tumor DNA (ctDNA) in patients with stage III colorectal cancer (CRC).</p><p>The pre-specified post-hoc analysis included 940 patients with available post-surgical plasma samples, who were randomized to receive FOLFOX +/- celecoxib, a non-steroidal anti-inflammatory drug (NSAID). Key findings included: Adding celecoxib to conventional chemotherapy in Signatera-positive patients, after surgery reduced the risk of cancer recurrence and death by ~40%. Celecoxib improved disease-free survival (DFS) (adjusted HR=0.61, 95% CI 0.42-0.89; 3-year 41.0% vs.</p><p>22.6%) and overall survival (OS) (adjusted HR=0.,62, 95% CI 0.40-0.96; 5-year: 61.6% vs. 39.9%) compared to placebo in Signatera-positive patient. Celecoxib benefit in Signatera-positive Patients was independent of demographic, pathologic or molecular factors, including PIK3CA status, further defining a patient population who may benefit from the addition to adjvant treatment.</p><p>Celecoxib improved DFS of Signatera-positive patients for both PIK3CA wild-type (adjusted HR=0.64, 95% CI 0. 42-0.98) and PIK3CA altered (adjusted HR=0.19, 95% CI 0.06-0.58) tumors.</p></div></div>

NTRA

<p>Natera, Inc. announced the publication of findings from the CALGB/SWOG 80702 study in JAMA Oncology, showing that adding celecoxib to chemotherapy in Signatera-positive colorectal cancer patients reduced recurrence and death risk by ~40%. Celecoxib improved disease-free and overall survival, independent of demographic or molecular factors, including PIK3CA status.</p>

Natera, Inc. Announces Publication of Signatera Analysis from Randomized, Phase III CALGB/SWOG 80702 Study in Colorectal Cancer